DIEGO ENRICO | Medicine and Dentistry | Best Researcher Award

Posted on by ScienceFather

Dr. DIEGO ENRICO | Medicine and Dentistry | Best Researcher Award

MD at Instituto Alexander Fleming, Argentina

Dr. Diego H. Enrico is an accomplished Medical Oncologist at the Alexander Fleming Cancer Institute in Buenos Aires, Argentina. He specializes in thoracic oncology and is the Coordinator of the Cancer Research and Innovation Unit. Dr. Enrico holds an MD from the University of Morón and completed his oncology residency at Eva Perón General Hospital. He further honed his expertise through a fellowship at the Gustave Roussy Cancer Center in Paris, focusing on translational and clinical cancer research. His research contributions include multiple clinical trials and numerous awards for his work in oncology, particularly in lung and prostate cancer. Dr. Enrico has co-authored several influential studies and received prestigious grants for cancer research. In addition to his clinical and research roles, he is an experienced educator and has served as co-director of research methodology programs. His ongoing work focuses on innovative cancer therapies and improving patient outcomes.

Profile:

Education

Dr. Diego H. Enrico holds a robust academic background in both medicine and business. He earned a Bachelor’s degree in Business Administration from N° 7 Educational School in Luján, Buenos Aires, graduating Summa Cum Laude in 2002 with an impressive 9.9/10 GPA. Pursuing his passion for healthcare, Dr. Enrico then attended the University of Morón School of Medicine, where he completed his MD degree in 2013, graduating Cum Laude with a GPA of 8.89/10. He further specialized in Medical Oncology through a postgraduate degree from the University of Buenos Aires between 2013 and 2015. Dr. Enrico has enhanced his expertise in clinical oncology with advanced studies abroad, completing the European University Diploma in Translational and Clinical Cancer Research and the University Diploma of Clinical Oncology at Université Paris XI, France, in 2019. His international training underscores his dedication to improving cancer research and patient care.

Professional Experiences 

Dr. Diego H. Enrico is a distinguished Medical Oncologist at the Alexander Fleming Cancer Institute in Buenos Aires, Argentina. Since June 2021, he has been an integral part of the Thoracic Oncology Unit, and in June 2022, he also joined the Clinical Research Unit. Dr. Enrico serves as the Coordinator of the Cancer Research and Innovation Unit (ETIC), a role he has held since March 2021. He has extensive experience in both clinical practice and research, specializing in thoracic oncology and leading innovative cancer research projects. Dr. Enrico has also contributed significantly to clinical trials, serving as a sub-investigator in multiple studies focusing on novel treatments for non-small cell lung cancer. His career is further highlighted by his previous fellowship at the prestigious Gustave Roussy Cancer Center in Paris, France, where he worked on translational and clinical research, particularly in thoracic oncology and drug development.

Research Interests

Dr. Diego H. Enrico’s research interests are centered around clinical oncology, with a particular focus on thoracic oncology and innovative cancer treatments. His work delves into the development of targeted therapies for non-small cell lung cancer (NSCLC), emphasizing the genetic and molecular underpinnings of the disease, such as EGFR mutations and KRAS mutations. Dr. Enrico actively participates in clinical trials, contributing to the advancement of combination therapies and immunotherapy strategies, including the use of novel agents like amivantamab, nivolumab, and pembrolizumab. He is also dedicated to improving patient outcomes through translational research, bridging the gap between laboratory findings and clinical applications. Additionally, Dr. Enrico’s interests include investigating biomarkers for cancer prognosis and the evaluation of treatment responses, as well as optimizing the safety and efficacy of cancer therapies through remote monitoring systems and real-life studies in oncology. His contributions significantly impact the field of precision medicine and personalized cancer care.

Research Skills

Dr. Diego H. Enrico possesses a broad range of research skills, particularly in the field of clinical oncology, with a strong focus on thoracic oncology. His expertise includes designing and conducting clinical trials, with experience in Phase I, II, and III trials for advanced malignancies and targeted therapies. As the Coordinator of the Cancer Research and Innovation Unit at the Alexander Fleming Cancer Institute, he has honed his abilities in translational cancer research, contributing to numerous studies on innovative treatments for non-small cell lung cancer. His proficiency in biostatistics, clinical research methodology, and the use of patient-reported outcomes to improve therapy adherence further highlights his analytical and strategic thinking. Additionally, Dr. Enrico has received several prestigious awards for his scientific contributions and has successfully led collaborative projects funded by international grants. His deep understanding of oncological biomarkers and personalized medicine makes him a leading researcher in the oncology field.

Award And Recognition 

Dr. Diego H. Enrico, a distinguished medical oncologist, has garnered numerous accolades throughout his career, highlighting his significant contributions to oncology. He has received multiple “Best Scientific Work” awards at prestigious conferences such as the XLIII and XLII Argentine Association of Clinical Oncology Post-Chicago Meeting and Update (2023, 2022) for his groundbreaking research in targeted therapy for lung cancer and prostate cancer treatments. Dr. Enrico was also honored at the First National Congress on Oncology for his work on adverse effects in clinical trials (2020) and has received several best poster awards for his research on prognostic factors in liver metastases and breast cancer. Additionally, his work in clinical research ethics earned him recognition from the Jaime Roca Foundation with the Annual Bioethics Award in 2018. Dr. Enrico’s achievements underscore his expertise and dedication to advancing cancer treatment and clinical research globally.

Conclusion

Dr. Diego H. Enrico is a strong candidate for the Best Researcher Award, particularly due to his significant contributions to thoracic oncology research, his leadership in clinical innovation, and his consistent recognition through awards. Strengthening his international presence and expanding his research focus could further elevate his profile as a leading researcher in the global oncology community.

Publication Top Notes
  • “Manifestations of Exile and Diaspora in the Poetry of Abdullah al-Baradouni”
  • “The Educational Technology’s Impact on Youth Creativity and Innovation: A Case of Ha’il Region of Saudi Arabia”
    • Authors: Harman Preet Singh; Mujahid Ahmed Mohammed Alwaqaa
    • Year: 2023
    • Source: Revista Amazonia Investiga
    • DOI: 10.34069/AI/2023.66.06.14
  • “The Impact of Globalization on Culture and Identity with Reference to Selected Works by Taha Hussein”
    • Authors: Mujahid Ahmed Mohammed Alwaqaa
    • Year: 2022
    • Source: Addaiyan Journal of Arts, Humanities and Social Sciences
  • “City Literature in Abdu al-Aziz al-Makkali’s Poetry”
    • Authors: Mujahid Ahmed Mohammed Alwaqaa
    • Year: 2021
    • Source: International Journal of Comparative Literature & Translation Studies
  • “Sociology and Literature: An Interdisciplinary Approach”
    • Authors: Mujahid Ahmed Mohammed Alwaqaa
    • Year: 2020
    • Source: Journal of Liberal Arts and Humanities
  • “A Sociological Study of Some Selected Poems by Hatim Altai”
    • Authors: Mujahid Ahmed Mohammed Alwaqaa
    • Year: 2020
    • Source: International Review of Humanities and Scientific Studies
  • “Literary Discourse and Human Rights in Martin Luther King’s Speech: I Have a Dream”
    • Authors: Mujahid Ahmed Mohammed Alwaqaa
    • Year: 2019
    • Source: Studies in Literature and Language
  • “The Allegorical Structure in Animal Farm”
    • Authors: Mujahid Ahmed Mohammed Alwaqaa
    • Year: 2019
    • Source: Al-Yemenia University

 

Ting-Ting Chang | Medicine and Dentistry | Best Researcher Award

Posted on by ScienceFather

Assoc Prof Dr. Ting-Ting Chang l Medicine and Dentistry l Best Researcher Award

Associate Professor at National Yang Ming Chiao Tung University, Taiwan

Dr. Ting-Ting Chang is an Associate Professor at National Yang Ming Chiao Tung University, specializing in vascular medicine, kidney disease, diabetes, and new drug development. With a Ph.D. from National Yang-Ming University, Dr. Chang has a robust publication record in high-impact journals, including Science Translational Medicine and Angiogenesis. Recognized with awards such as the Young Scientists Award and the Young Investigator Fellowship, Dr. Chang is also a full member of Sigma Xi and other prestigious societies. Their research is notable for its innovation and significant contributions to understanding and treating complex diseases.

Profile:

Education

Ting-Ting Chang, Ph.D., earned her Ph.D. in Pharmacology from National Yang-Ming University in Taipei, Taiwan, in 2015. Her educational journey is distinguished by her continued academic and research excellence, which laid a strong foundation for her current role as an Associate Professor in the Department and Institute of Pharmacology at National Yang Ming Chiao Tung University. Prior to this, Dr. Chang completed her post-doctoral research at the same institution, further solidifying her expertise in pharmacology and related fields.

Professional Experience

Ting-Ting Chang, Ph.D., is an accomplished researcher and academic with extensive experience in the field of pharmacology. Currently serving as an Associate Professor at the Department and Institute of Pharmacology, National Yang Ming Chiao Tung University, Dr. Chang has previously held roles as an Assistant Professor and Post-doctoral Researcher at the same institution. Their career spans significant contributions to vascular medicine, kidney disease, diabetes, and new drug development, with a track record of high-impact research and numerous publications in leading scientific journals.

Research Interest

Ting-Ting Chang’s research interests encompass a broad range of topics within vascular medicine and molecular biology, focusing on the mechanisms underlying vascular dysfunction, kidney disease, and diabetes mellitus. Her work includes experimental animal model design and new drug development, aiming to uncover novel therapeutic targets and strategies for these critical health issues. Dr. Chang’s research integrates molecular and cellular approaches to address complex pathological conditions, contributing significantly to advancements in understanding and treating vascular and metabolic disorders.

Research Skills

Ting-Ting Chang, Ph.D., demonstrates exceptional research skills through a robust portfolio of high-impact publications and significant contributions to fields such as vascular medicine, kidney disease, and diabetes. With a strong academic background and extensive experience as both an Associate Professor and Post-doctoral Researcher, Dr. Chang excels in designing and conducting innovative studies, particularly in identifying novel therapeutic targets and mechanisms. Their proficiency in experimental animal model design and new drug development further highlights their expertise, while their membership in prestigious scientific societies and receipt of notable awards underscore their recognition and influence in the research community.

Award and Recognition

Ting-Ting Chang, Ph.D., has garnered significant awards and recognition throughout their career, underscoring their outstanding contributions to research. Notably, Dr. Chang received the Young Scientists Award at the 55th Annual Scientific Meeting of the Japan Atherosclerosis Society in 2023 and the Young Investigator Fellowship Award at the 88th European Atherosclerosis Society Congress in 2020. In addition, Dr. Chang was awarded full membership of Sigma Xi in 2023, reflecting their esteemed position in the scientific community and their impactful research in vascular medicine, kidney disease, and diabetes.

Conclusion

Ting-Ting Chang, Ph.D., is a highly qualified candidate for the Best Researcher Award. Their exceptional contributions to vascular medicine, kidney disease, and diabetes, along with a strong publication record and recognition in the scientific community, underscore their suitability for this award. Addressing areas for improvement, such as expanding research applications and increasing public engagement, could further enhance their profile as a leading researcher. Overall, Dr. Chang’s dedication, innovative research, and professional achievements make them an excellent contender for the Best Researcher Award.

Publication Top Notes

  • Association between vitiligo and risk of retinal detachment: a population-based cohort study in Taiwan
    • Authors: Chen, C.-L., Wu, C.-Y., Chen, Y.-L., Chang, Y.-T., Wu, C.-Y.
    • Year: 2024
    • Citations: 0
  • Rejuvenation of the dorsal hand by injectable poly-D, L-lactic acid: A pilot study
    • Authors: Ma, S.-H., Lin, C.-Y., Lin, J.-Y., Chang, Y.-T., Chen, C.-C.
    • Year: 2024
    • Citations: 0
  • Correlation of Disease Severity, Proinflammatory Cytokines, and Reduced Brain Gray Matter Volumes in Patients with Atopic Dermatitis
    • Authors: Li, C.-Y., Chang, W.-C., Chen, M.-H., Chen, Y.-Y., Bai, Y.-M.
    • Year: 2024
    • Citations: 0
  • Risk of Type 1 Diabetes Mellitus in Patients with Atopic Dermatitis: A Nationwide Population-Based Cohort Study
    • Authors: Li, M.-C., Wu, C.-Y., Chang, Y.-T., Lyu, Y.-S., Wu, C.-Y.
    • Year: 2023
    • Citations: 0
  • Assoziation zwischen chronischer Nierenerkrankung und dem Risiko für bullöses Pemphigoid: eine nationale bevölkerungsbasierte Kohortenstudie
    • Authors: Yu, W.-T., Ma, S.-H., Wu, C.-Y., Chang, Y.-T., Wu, C.-Y.
    • Year: 2023
    • Citations: 1